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Abstract 
In this study we have demonstrated that the modification of hyaluronan (hyaluronic acid; Hya) with 
sulfate groups led to different binding affinities for recombinant human bone morphogenetic protein-4 
(rhBMP-4). The high-sulfated sHya2.8 (average degree of sulfation (D.S.) 2.8) exhibited the tightest 
interaction with rhBMP-4 followed by the low-sulfated sHya1.0 as determined with surface plasmon 
resonance (SPR), ELISA as well as competition ELISA. Unmodified Hya, chondroitin-sulfate (CS) and 
heparan sulfate (HS) showed significantly less binding affinity. SPR data could be fitted to an A + B = 
AB Langmuir model and binding constants were evaluated ranging from 13 pM to 5.45 µM. The 
interaction characteristics of the differentially sulfated Hyas are promising for the incorporation of these 
modified polysaccharides in bioengineered coatings of biomaterials for medical applications. 
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(CS), ELISA, hyaluronic acid/hyaluronan. 
Introduction 
 Hyaluronan (Hya) is unique among glycosaminoglycans with respect to not being covalently bound 
to a polypeptide. The linear polymer has a relatively simple structure of repeating non-sulfated 
disaccharide units composed of D-glucuronic acid [β-1-3] and N-acetyl-D-glucosamine [β-1-4]. The 
polysaccharide is apparently of vital importance because no inherited disease is known in which it is 
lacking1-3. Hya directly affects tissue organization by activating signaling pathways via CD44 cell-
surface receptors2. In vitro, Hya promotes cell migration, cell adhesion4-6 and differentiation in 
development. Furthermore it modulates the inflammatory response7, ECM (extracellular matrix) 
remodelling8 and wound healing2, 3, 9, 10. Huang and co-workers have presented molecular-weight-
dependent positive effects of Hya on osteoblast proliferation and differentiation11. Hya is especially 
appropriate for tissue engineering applications because of its non-immunological properties, widespread 
availability and ease of chain manipulation6. Extensive efforts have been made by various laboratories 
to produce derivatives of Hya with additional unique properties for specific biomedical applications. A 
wide variety of Hya derivatives are currently used for eye surgery, joint viscoelastic supplementation, 
and anti-adhesion films12. 
By chemically cross-linking high-molecular-weight Hya biocompatible and biodegradable hydrogels 
have been formulated for the delivery of bone morphogenetic proteins (BMPs)1, 13, 14. Hydrogel-rhBMP-
2 composite implants have been shown to induce endochondral bone formation at heterotopic sites1 and 
heal critically sized skull defects in rabbits13, 15.  
Another interesting form of modification is the introduction of sulfate groups. Sulfated Hya (sHya) 
exhibits high activity and biocompatibility with cells: Yamada et al. have demonstrated the effect of 
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3 
sHya on normal human astrocytes activity and supporting role in neuron survival16. The sulfate group of 
sHya seems to enhance expression of cell adhesion proteins in rat calvarial osteoblast cells resulting in 
aggregate formation and further remarkable induction of the alkaline phosphatase activity17.  
Furthermore, naturally occurring sulfate groups in glycosaminoglycan (GAG) chains like 
heparin/heparan sulfate (HS) have been identified as important determinants of protein-binding sites. 
They are introduced during the process of polymer modification. Heparin shows a high proportion of O-
sulfated disaccharide units and a relatively homogeneous overall sulfation pattern, whereas HS is 
composed of alternating sulfated and non-sulfated sequences of variable length18-20. Interactions 
between GAGs and proteins may be highly specific, as illustrated by binding of heparin/HS to 
antithrombin21. Other proteins, such as histones, bind GAGs due to their overall basic character, without 
any apparent need for a specific saccharide sequence22, 23. HS chains are known to interact with a variety 
of proteins such as heparin-binding growth and differentiation factors (HBGFs), morphogens, 
extracellular matrix components, protease inhibitors, proteases, lipoprotein lipases, and various 
pathogens. The interaction of growth factors/GAGs could be of importance in i) stabilizing the protein 
with respect to denaturation as well as proteolysis at normal physiological ionic strength, pH, and 
temperature, ii) preventing the diffusion of the growth factor within a tissue compartment or between 
tissue compartments, as well as allowing locally stored growth factors to act on a restricted number of 
cells, iii) enabling or promoting growth-stimulatory activities by stabilizing interactions between growth 
factors and receptors and iv) playing a critical role in regulating growth factor availability by controlling 
the deposition of latent growth factor binding proteins into the ECM24-27.  
Heparin dose dependently enhances the osteoblast differentiation induced not only by homodimers of 
BMP-2 or BMP-4 but also heterodimers of BMP-2/6 or BMP-2/728. Heparin also appears to potentiate 
BMP-2 activity by inducing the synthesis of proteoglycans in embryonic limb bud cells29.  
HS and dextran sulfate also enhanced the BMP-2 activity, while chemically desulfated heparin-
derivatives have lost this stimulatory capacity. This suggests that sulfated polysaccharides enhance the 
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4 
biological activity of BMPs by presenting the ligands to their signaling receptors expressed on cell 
membranes28. 
Heparin-binding determinants are located in the N-terminal segments of BMPs as indicated by the 
complete loss of high affinity binding in a BMP-2 variant in which the N-terminal residues of BMP-2 
had been substituted by a dummy sequence of equal length. The most prominent difference between the 
N-terminal sequence of the variant and that of BMP-2 is the lack of five basic side chains (K3, H4, K5, 
R7, K11). It can be concluded that these residues contribute to heparin binding. Similar basic residues 
albeit with a slightly different spacing exist in the N-termini of BMP-4 and the Drosophila dpp 
protein29. Therefore it seems to be a feasible approach to investigate Hya derivatives with varying type 
and content of anionic groups for their growth factor binding activities creating new forms of Hya for 
biomedical applications. These forms could then enhance the osteoinductive properties of biocompatible 
Hya by specifically interacting with stimulating factors of growth and differentiation. Members of the 
TGF-β1 growth factor superfamily, in particular TGF-β1, BMP-2 and -4 are potent bone inducing 
factors and good candidates for this kind of interaction. 
  In this study we investigated the interaction of sHya with high and with low degree of sulfation (D.S.) 
in comparison with CS and HS (Figure 1) to the bone inducing growth factor recombinant human BMP-
4 using immunological and biophysical methods, i.e. enzyme linked immunosorbent assay (ELISA) and 
surface plasmon resonance (SPR).  
 
Materials and Methods 
Materials. Hya (from Streptococcus, MW = 1.1 x 10E+6 g mol-1) was obtained from Aqua Biochem, 
Dessau, Germany, sulfur trioxide/dimethylformamide complex (SO3-DMF, purum, ≥ 97 %, active SO3 
≥ 48 %) and sulfur trioxide/pyridine complex (SO3-pyridine, pract.; ≥ 45 % SO3) from Fluka Chemie, 
Buchs, Switzerland. Bovine tracheal chondroitin-sulfate sodium salt (CS; a mixture of 70% chondroitin-
4-sulfate or CS-A and 30% chondroitin-6-sulfate or CS-C) and heparan sulfate sodium salt from bovine 
Page 4 of 25
ACS Paragon Plus Environment
Submitted to Biomacromolecules
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review. Confidential - ACS
 
5 
kidney (HS; according to the supplier with a sulfur content of 5-7 %) were purchased from Sigma-
Aldrich, Schnelldorf, Germany. Recombinant human rhBMP-4 as well as mouse anti-human BMP-4 
antibodies was obtained from R&D Systems, Wiesbaden-Nordenstadt, Germany. The sensor chip CM5, 
the amine coupling kit and HBS-EP buffer were all purchased from GE Healthcare Europe GmbH, 
Freiburg, Germany.  
Methyl-/vinyletheranhydrid-copolymer and adipinic acid dihydrazide were purchased from Fisher 
Scientific GmbH, Nidderau, Germany. Sodium cyanoborohydride, bovine serum albumin (BSA), Tween 
20, Sucrose, 4-nitrophenylphosphate disodium salt hexahydrate and 3,3´,5,5´-tetramethylbenzidine 
liquid substrate were available from Sigma-Aldrich, Schnelldorf, Germany. The biotin-conjugated goat 
anti-mouse antibody was purchased from Dianova, Hamburg, Germany.  
Preparation of Hya sulfates (sHya).  
General procedures 
The tetrabutylammonium salt of Hya (TeBA-Hya) was used as reactant for the sulfation and prepared as 
follows: 2.0 g (4.98 mmol) of Hya (sodium salt) were dissolved in bidistilled water (400 ml) at room 
temperature over night. The solution was stirred with 20 g of Dowex WX 8 ion exchanger 
(tetrabutylammonium-form) over night and after filtration, the polymer solution was lyophylized and 
dried under vacuum at 40°C. Yield: 90%.  
High-sulfated HA (sHya2.8) 
2.0 g (3.22 mmol) of TeBA-Hya was suspended under argon at room temperature in DMF (400 mL). 
9.9 g (64.4 mmol) of the SO3-DMF complex dissolved in 40 ml DMF, were added (polymer : SO3 ratio 
= 1 : 20) and the reaction solution was stirred for 1 h at room temperature. Yield: 70% (related to Hya-
Na).  
Low-sulfated HA (sHya1.0)  
3.6 g (22.54 mmol) of the SO3-pyridine complex, dissolved in 40 ml DMF, was added to a suspension 
of 2.0 g (3.22 mmol) of TeBA-Hya in DMF (400 mL; molar polymer : SO3 ratio = 1 : 7) under argon at 
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6 
room temperature. The reaction solution was stirred for 20 min. Yield: 65% (related to Hya-Na). In both 
cases the sulfated products were isolated from the reaction mixture by precipitation into acetone (2.8 L) 
and neutralized using ethanolic NaOH solution. The formed sodium salt of the sHya were washed 
several times with acetone and purified by dialysis against distilled water followed by lyophilization of 
the aqueous solutions and drying of the resulting polymers under vacuum. 
Characterization of sHya and CS. NMR spectra were recorded in D2O (99.9%, Sigma-Aldrich, 
Schnelldorf, Germany), with a Bruker Advance 400 MHz spectrometer at a temperature of 373 K. D2O 
at 4.75 ppm was used as reference line. The KBr technique was employed for recording FT-IR spectra 
with a FT-IR-Spektrometer FTS 175 (Bio-Rad, Krefeld, Germany). Molecular weight determination was 
performed by gel permeation chromatography (GPC) analysis using the following equipment: Jasco PU 
980 pump, Postnova Analytics PN 3000 (15°) laser light scattering (LLS) detector, Jasco RID-1531 
refraction (RI) detector, and a combination of 3 Suprema-Gel columns with dimensions of 8 mm x 300 
mm (diameter x length) and the specifications 10 µm - 100 Å, 10 µm – 1,000 Å and 20 µm – 30,000 Å 
referring to grain size and pore size, respectively. The eluent was PBS buffer and the flow rate for all 
columns was 0.8 ml/min. Concerning refraction index detection, the system was calibrated with 
standard pullulan (PSS, Mainz, Germany). LLS detection of analytes was used for the determination of 
molecular weight values (number-average and weight-average molecular weights Mn and Mw) and RI 
detection for the estimation of the polydispersity (PD) indices. The D.S. of the sHya was determined by 
estimation of the sulfur content using an automatic elemental analyzer (CHNS-932, Leco, 
Mönchengladbach, Germany). Analytical data are given in Table 1 and Figure 2. 
Immobilization of rhBMP-4 on CM5 biosensor chip surfaces. For interaction analysis of growth 
factor and GAGs a BIAcore3000 instrument with BIAcore Control and BIAevaluation software 4.1 
was used. RhBMP-4 was immobilized on the surface of a CM5 sensor chip using the amine coupling 
reaction as described by the manufacturer, where the protein’s primary amino groups reacted with 
carboxymethylated dextran, yielding a stable covalent bond. Carboxymethylated dextran covers the 
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7 
surface of the gold film in the sensor chip, providing a hydrophilic environment conducive for the 
interaction of biological molecules. Briefly, the carboxymethylated dextran surface was activated using 
an injection pulse (7 min, 35 µL) containing a mixture of 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS). Protein immobilization was 
accomplished by injecting 30 µL of rhBMP-4 with a concentration of 10 µg/mL in 10 mM sodium 
acetate buffer at pH 5.5. The remaining non-reacted sites on the sensor surface were blocked with a 35 
µL injection of 1 M ethanolamine-HCl pH 8.5. One flow cell was used as a reference surface and was 
directly deactivated after the injection pulse of EDC/NHS by injecting 1 M ethanolamine-HCl without 
the immobilization of rhBMP-4. All steps were carried out in a continuous flow of HBS-EP (0.01 M 
Hepes (pH 7.4), 0.15 M NaCl, 3 mM EDTA, 0.005% surfactant P20) running buffer at 5 µL/min and all 
buffers were degassed prior to use.  
SPR measurements of growth factor interaction with GAGs. The baseline was allowed to stabilize 
for at least 2 h in HBS-EP running buffer before injecting test samples. Each GAG sample was prepared 
in HBS-EP buffer and injected for 3 min at 30 µL/min followed by a 2 min dissociation phase. The 
sensor surface was regenerated using 30 µL 3 M NaCl. Re-equilibration between the sensor surface and 
running buffer was established prior to injection of the next sample by a 2 min pre-run phase. The 
response was monitored as a function of time (sensorgram) at 25°C and subtracted from the response of 
the reference surface. Kinetic parameters were evaluated using the BIAevaluation software 4.1.   
Covalent coupling of GAGs to MaxiSorp™ 96-well ELISA-plates. The polysaccharides were 
immobilized in each well of MaxiSorp™ 96-well microtiter plates from Thermo Fisher Scientific (Nunc 
GmbH & Co. KG, Lengenselbold, Germany) via their reducing ends. In brief, 50 µg GAGs were 
solubilized in 25 mM citric acid supplemented phosphate buffer pH 5.0 and incubated over night with 
96-well plates pre-treated for 30 min with methyl-/vinyletheranhydride-copolymer in DMSO, followed 
by 2.5 h with adipic acid dihydrazide. The resulting Schiff´s bases are reduced to stable alkylamine 
bonds covalently linking the GAGs to the dish by incubating them for 30 min with 1% sodium 
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8 
cyanoborohydride in methanol. The prepared surfaces were then washed with 10 mM Tris/HCl, 50 mM 
sodium chloride, pH 7.4 (TBS) and blocked for 2 h with 2% BSA in TBS. For non-specific binding 
untreated wells were incubated with 2% BSA in TBS and untreated wells with no additions were used 
as positive control for growth factor binding. 0 - 100 ng/ml (0 - 5 ng) of rhBMP-4 in phosphate buffered 
saline (PBS) with the addition of 1% BSA were then incubated with the prepared surfaces over night at 
4°C. 
Enzyme linked immunosorbent assay (ELISA). The amount of bound growth factors was 
determined directly on the MaxiSorp™ 96-well microtiter plates coated with GAGs (Direct-ELISA) or 
indirectly in the solution containing non-bound rhBMP-4 (Sandwich-ELISA) recovered from the 
supernatant after incubation with immobilized GAGs. A calibration curve ranging from 0 ng/ml - 50 
ng/ml (0 - 2.5 ng) in 1% BSA/PBS was prepared for rhBMP-4 to calculate the amount of non-bound 
growth factors. All binding data are the average of triplicates and statistically analyzed by two-way 
ANOVA with means comparison using Tukey test. 
In brief, up to 5 ng of rhBMP-4 were incubated for 16 h with immobilized GAGs on 96-well ELISA-
plates at 4°C for binding to reach equilibrium. The supernatants were removed and transferred to 
another MaxiSorp™ 96-well microtiter plate pre-coated with growth factor specific capture antibodies 
for Sandwich- ELISA and blocked with 1% (w/v) BSA, 5% Sucrose (w/v), 0.05% (v/v) Tween 20 in 
PBS.  
The Direct-ELISA plates were blocked with 3% (w/v) BSA, 0.05% (v/v) Tween 20 in PBS for 1.5 h 
at room temperature, washed with 0.05% (v/v) Tween 20 in PBS, and then incubated with primary 
antibody for 2 h at room temperature. The plates were incubated with biotin-conjugated goat anti-mouse 
antibodies for 1 h followed by alkaline phosphatase-conjugated streptavidin for 1 h. Antibodies and 
alkaline phosphatase-conjugated streptavidin were diluted in 0.5% (w/v) BSA, 0.05% (v/v) Tween 20 in 
PBS, respectively. Inbetween each incubation step the wells were washed with 0.05% Tween in PBS. 
The wells were developed with 4-nitrophenylphosphate disodium salt in 0.1 M glycine, 1 mM MgCl2, 1 
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9 
mM ZnCl2, pH 10.4. The reaction was allowed to proceed for 10-20 min and then stopped with 3 M 
NaOH and measured at A405 nm using a microtiter plate reader. 
After washing with 0.05% (v/v) Tween 20 in PBS the Sandwich-ELISA plates were incubated with 
biotinylated growth factor specific antibodies diluted in PBS for 2 h. Following a washing step 
streptavidin-horseradish peroxidase diluted in 1% BSA/PBS was added to the wells for 20 min. The 
plates were developed with 3,3´,5,5´-tetramethylbenzidine liquid substrate. The reaction was stopped 
with 1 M H2SO4 and measured at A450 nm using a microtiter plate reader.  
Competitive binding inhibition using dissolved GAGs. A competitive inhibition ELISA assay using 
dissolved GAGs to compete for growth factor binding to a sHya2.8-immobilized surface was further 
employed to assess the differences in affinity and the specificity of the interaction between GAGs and 
rhBMP-4. 
For competition experiments, the procedure was as detailed as for Direct-ELISA, except that a 
constant concentration of 2.5 ng of growth factor was incubated with variable concentrations (10-2 - 10-9 
g/ml) of dissolved competitors in 1% (w/v) BSA, PBS. The data were fitted with a four-parameter 
logistic equation and plotted on a semi-logarithmic scale using non-linear regression with Origin 
software. Data were plotted for each protein, and in the following the amount of GAG required to 
inhibit 50% of binding to each surface was determined. All binding data are the average of triplicates. 
Results 
Characterization of sHya and CS. The synthesis of sHya derivatives using different SO3 complexes 
(SO3-pyridine and SO3-DMF) as sulfating agents led to a low-sulfated sHya (sHya1.0, D.S. = 1.0) and a 
high-sulfated form (sHya2.8, D.S. = 2.8; Figure 1). 
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  heparan sulfate (HA): R = H or SO3Na; R' = COCH3 or SO3Na
OO
OH
O
OH O
NH
OHNaO3SOCOONa
O
chondroitin-4-sulfate, Na-salt (CS-A)
OOO
R'O O
NH
OR
R'O
COONa
O
OR'
hyaluronic acid, Na-salt (Hya): R, R' = H
low-sulfated Hya (sHya1.0): R = SO3Na, R' = H
high-sulfated Hya (sHya2.8): R = SO3Na, R' = H or SO3Na
1
23
4
5
6
1'
2'3'
4'
5'
6'
O
OR
O
RO O
COONa
OR
RO
NH
R'
O
O
 
Figure 1. Chemical structures of glycosaminoglycans tested for binding to rhBMP-4. 
 
13C-NMR spectroscopy was employed to study the distribution of introduced sulfate groups within 
the disaccharide repeating unit of Hya. Comparing the 13C-NMR spectra of unsubstituted Hya and both 
the sulfated derivatives sHya1.0 and sHya2.8 (Figure 2), a low-field shift of the C-6-signal of the 
primary CH2-group in the N-actetyl-glucosamine unit from 61 ppm to 68 ppm was observed after 
sulfation. A nearly complete sulfation of the C-6-position might therefore be assumed even in the case 
of the low-sulfated derivative sHya1.0. 
Except for C-6, the carbon signals of the low-sulfated sHya1.0 show chemical shifts similar to the 
ones of unsubstituted Hya allowing a full assignment of the different carbon signals. In contrast the 
complete assignment of the signals in the 13C-NMR spectra of the high-sulfated sHya2.8 is difficult 
because of the complexity of the obtained spectrum. 
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Figure 2. 13C-NMR spectra for substituent distribution of unmodified and of modified Hya sHya2.8 and 
sHya1.0. 
Nevertheless, from the obtained spectroscopic data it can be postulated that in the high-sulfated 
derivative sHya2.8 besides a complete sulfation of the primary OH-group at C-6, sulfation also occurs, 
to a lesser extent on the remaining secondary OH groups of the N-acetylglucosamine unit (C-4) and the 
glucuronic acid unit (C-2’, C-3’). The C-4-position might be sulfated to a slightly higher extent than 
both of the OH-groups at C-2’ and C-3’. As shown in Table 1, the Hya educts undergo a decrease in 
their molecular weight during the sulfation reaction. Starting from Hya with a weight-average molecular 
weight (MW) of 10E+6 g mol-1, the Mw of sHya dropped down to less than 10E+5 g mol-1. Interestingly, 
sulfation leads to a molecular weight distribution which is considerably narrower as is illustrated by the 
determined lower PD values. As LLS detection can lead to a discrimination of low molecular-weight 
fractions of the measured polymers (~5 - 50,000 g/mol) resulting in inaccurately narrow molecular 
weight distributions, the calculation of polydispersity PD was performed on the basis of Mn and Mw 
values measured by RI detection.  
 
Sample Hya sHya2.8 sHya1.0 CS HS 
Sulfur content [%] - 13.1 6.6 4.9 4.7 
D.S. 0.0 2.8 1.0 0.9 n.d. 
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12 
Mn [g mol-1] 1,020,000 (LLS) 
395,000 (RI) 
46,000 (LLS) 
72,000 (RI) 
29,000 (LLS) 
38,000 (RI) 
15,000 (LLS) 
49,000 (RI) 
n.d. 
Mw [g mol-1] 1,175,000 (LLS) 
1,895,000 (RI) 
74,000 (LLS) 
121,000 (RI) 
33,000 (LLS) 
79,000 (RI) 
18,000 (LLS) 
67,000 (RI) 
n.d. 
PD 4.80 1.68 2.08 1.37 n.d. 
 
TABLE 1: Characteristics of Hya, synthesized Hya derivatives and CS. D.S., number-average (Mn) and 
weight-average (Mw) molecular weights as determined by LLS detection and RI detection. Molecular 
weight distributions (polydispersity index: PD) based on the values calculated from RI detection; n.d.: 
not determined. 
SPR-analysis of GAG-growth factor interaction. Varying concentrations of GAGs were injected 
over the sensor chip surface with immobilized rhBMP-4, and the change in response was evaluated as a 
function of time. Initially, HBS-EP running buffer was injected over the surface, and the response was 
taken as the reference value. In the following the GAG solution was injected (Figure 3, Arrow A), and 
the increasing response corresponded with the association of the GAGs with rhBMP-4. In the final 
phase, the fluid passing over the surface again contained only running buffer (Figure 3, Arrow D), 
which allowed the carbohydrate to dissociate from the protein due to a concentration gradient, thereby 
causing a slight decrease in the measured response. Resulting data were corrected by the response of a 
blank flow cell treated only with coupling chemistry. Figure 3 depicts the sensorgrams for the binding 
of a sHya2.8 concentration series to rhBMP-4, displaying an increasing response with growing 
concentration.  
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Figure 3. SPR sensorgrams of the interaction of sHya2.8 with immobilized rhBMP-4 at T = 25°C. 
Sensorgrams of the rhBMP-4/sHya2.8 interaction were run at different concentrations of sHya2.8 (in 
ng/ml) in running buffer: 16, 31, 63, 125, 188, 250. The flow rate was 30 µl/min. Arrow A represents 
the starting point of the sample injection or the beginning of the association phase. Arrow D represents 
the end of the sample injection or the beginning of the dissociation phase. 
Figure 4 displays a comparison of the interactions of different GAGs with rhBMP-4 at certain 
concentrations. The response for the interaction of unmodified Hya, CS, and HS at 50 µg/ml is 
considerably smaller than for sHya1.0 at 10 µg/ml. To reach an analogous response to the interaction 
between rhBMP-4 and sHya2.8, sHya1.0 concentrations in the range of µg/ml are necessary compared 
to ng/ml for sHya2.8 (Figure 3 and 4). 
The affinity of GAGs for rhBMP-4 was quantified by determining the overall dissociation constant 
KD (KD = koff/kon), where koff and kon represent dissociation and association rate constants calculated 
from the dissociation and the association phase of the curves, respectively (Table 2).  
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Figure 4. SPR sensorgrams of the interactions of different GAGs with immobilized rhBMP-4 at T = 
25°C. Sensorgrams for sHya1.0 were run at concentrations of 250 ng/ml, 5 µg/ml and 0.25 mg/ml, those 
for unmodified Hya, CS, and HS at 50 µg/ml. The flow rate was 30 µl/min. 
GAG 
 derivative 
kon [1/Ms] 
 
koff [1/s] 
 
KD [nM]  Chi2 
sHya2.8 2.26*10E7 4.58*10E-4 0.020 7.78 
 2.25*10E7 2.94*10E-4 0.013 7,04 
sHya1.0 3.91*10E4 4.47*10E-4 11.4 12.5 
 4.42*10E4 3.24*10E-4 7.3 7.78 
HS 2.73*10E2 1.49*10E-3 5450  1.84 
 2.68*10E2 1.32*10E-3 4940 0.62 
 
TABLE 2: Kinetic rate constants (kon and koff) and equilibrium binding constants (KD) for the 
interaction of GAGs and immobilized rhBMP-4 after fitting with BIAevaluation software 4.1 applying  
a A+B=AB Langmuir binding model. 
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The differences of the association rates between the sulfated GAGs were evaluated after fitting the 
binding data to an A + B = AB Langmuir model with BIAevaluation software 4.1 (Table 2). Naturally 
sulfated HS (2.68 - 2.73*10E+2 1/Ms) exhibits a five orders of magnitude lower kon value compared to 
sHya2.8 (2.25 - 2.26*10E+7 1/Ms), and a two orders of magnitude lower kon value than sHya1.0 (3.91 - 
4.42*10E+4 1/Ms). While sHya2.8 and sHya1.0 had comparable dissociation rate constants koff (2.94 - 
4.58*10E-4 1/s), they were three to five times lower than for HS (1.32 - 1.49 *10E-3 1/s). The highest 
affinity, expressed as equilibrium dissociation constant KD, could be determined for the interaction of 
rhBMP-4 with sHya2.8 (13 - 20 pM) followed by sHya1.0 (7.3 nM - 11.4 nM). HS exhibited a 
considerably lower affinity (4.94 µM - 5.45 µM) to rhBMP-4 than sHya2.8 and sHya1.0. 
Enzyme linked immunosorbent assay (ELISA). The binding of dissolved rhBMP-4 to GAGs 
immobilized on microtiter wells was performed by incubating up to 5 ng of growth factor in 1% 
BSA/PBS. In the following Direct-ELISA the highest amount of bound rhBMP-4 was found in wells 
coated with the high-sulfated sHya2.8, closely followed by the low-sulfated form sHya1.0 (p < 0.01) as 
shown in Figure 5. In contrast, for unmodified Hya, HS and CS coated surfaces significantly (p < 0.001) 
less bound protein could be detected. However, all surfaces with immobilized GAGs retained 
significantly (p < 0.001) more rhBMP-4 than those covered with BSA.  
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Figure 5. Direct-ELISA of up to 5 ng rhBMP-4 in 1% BSA/PBS with GAGs immobilized on wells of 
MaxiSorp™ 96-well microtiter plates. Surfaces coated with 2% BSA or untreated wells, the latter 
incubated with rhBMP-4 in PBS, served as negative or positive controls. The colorimetric reaction was 
followed at A405 nm. Binding data are the average of triplicates. 
In the Sandwich-ELISA (Figure 6) the amount of the non-bound rhBMP-4 was determined in the 
supernatant as opposed to the bound growth factor detected directly on the surface of the Direct-ELISA 
plate. In the positive control no rhBMP-4 was found in the supernatant, demonstrating that everything 
had bound to the uncoated wells. In contrast, ~1.8 ng of rhBMP-4 (of 5 ng originally incubated growth 
factor) were bound non-specifically to the surface in wells blocked with 2% BSA. Again coatings with 
GAGs retained significantly more rhBMP-4 than the BSA reference surface (p < 0.001), with CS (~2.3 
ng of 5 ng) exhibiting the smallest amount bound and sHya2.8 the highest (~3.5 ng of 5 ng). As in the 
Direct-ELISA, sHya2.8 and sHya1.0 showed significantly more retained rhBMP-4 than unmodified 
Hya, HS and CS (p < 0.001 and p < 0.05, respectively). Differences between HS and CS were not 
statistically significant. 
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Figure 6. Sandwich-ELISA of the supernatants containing the non-bound rhBMP-4 recovered after 
incubation of up to 5 ng rhBMP-4 with immobilized GAGs. The amount of bound growth factor was 
determined indirectly by comparison to a calibration curve of rhBMP-4. The colorimetric measurement 
was performed at A450 nm. Binding data are the average of triplicates.  
   Competitive inhibition of binding using dissolve  GAGs. To confirm the specificity of the 
interactions of rhBMP-4 with GAGs, the abilities of different dissolved GAGs to compete with the 
interaction were investigated. A constant amount of rhBMP‐4 was incubated with a surface displaying 
immobilized sHya2.8, but in the presence of varying amounts of free GAGs. The residual binding was 
determined at each concentration of dissolved GAGs by Direct-ELISA. Figure 7 shows that all 
dissolved GAGs tested are less potent competitors of the interaction of rhBMP-4 with immobilized 
sHya2.8 than dissolved sHya2.8 itself. The low-sulfated sHya1.0 (IC50 4.5*10E-7 g/ml ± 2.1*10E-7 
g/ml) exhibited two orders of magnitude weaker competition abilities than sHya2.8 (IC50 1.3*10E-9 
g/ml ± 6.8*10E-9 g/ml). In comparison to the sulfated Hya derivatives, unmodified Hya, CS and HS are 
much weaker competitors. The results obtained showed a ranking of binding affinities as sHya2.8 > 
sHya1.0 > unmodified Hya ≈ CS > HS.  
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Figure 7. Competitive inhibition of rhBMP-4 binding to immobilized sHya2.8 using varying 
concentrations of dissolved GAGs. A Direct-ELISA of 2.5 ng rhBMP-4 in 1% BSA/PBS was performed 
and the colorimetric measurement was recorded at A405 nm. Values are the means of triplicates and data 
are representative of two separate experiments. 
 
Discussion 
The major goal of this study was to investigate the growth factor binding abilities of Hya modified 
with sulfate groups, aiming at a deeper understanding of structure-function relationships of Hya 
derivative interactions with biological mediators. 
To this end high-sulfated Hya (D.S. ~ 2.8) and low-sulfated Hya (D.S.
 
~
 
1.0) were prepared and 
characterized. The 13C-NMR spectra of sHya proved that the primary OH-group at the C-6 position in 
N-acetylglucosamine is preferentially sulfated, followed by the secondary OH-group at C-4. This 
sulfation of the C-4 and the C-6 seems to be of special importance for binding to BMP-4, as Miyazaki et 
al. could show that C-4, C-6-disulfation of galactosamine in chondroitin sulfate E is necessary for high 
affinity30, while BMP-7, another member of the TGF-β growth factor superfamily, requires 6-O- and N-
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sulfation of the N-acetyl-glucosamine unit for binding to HS31. The C-6 modification is the only sulfate 
group that is post-synthetically edited by the cell surface sulfatases, and in addition to influencing 
binding has been shown to affect growth factors signaling, specifically for Wnt, FGF2 and BMP20.  
Several studies have quantified the rate constants as well as the affinities of interactions between 
proteins and GAGs, in particular heparin or HS chains using optical biosensors24, 29, 32-34, clearly 
demonstrating the ability of the SPR technique to generate kinetic data as well as binding constants in 
this context. Our own data proved a concentration dependency of the interaction between GAGs and 
rhBMP-4 (Figure 3). The results indicated that the sulfated Hya derivatives exhibit fast on-rate (kon) and 
slow off-rate (koff) kinetics for rhBMP-4 with KD values ranging from 13 pM to 11.4 nM (Table 2).  
According to these KD values, sHya2.8 (13 - 20 pM) exhibited the tightest binding to immobilized 
rhBMP-4, followed by sHya1.0 (7.3 - 11.4 nM) with the interaction being three orders of magnitude 
stronger for sHya2.8. This difference is due to the three orders of magnitude faster association rate of 
sHya2.8 (2.25 - 2.26*10E+7) compared to sHya1.0 (3.91 - 4.42*10E+4) Interestingly, HS with an only 
slightly lower sulfur content than sHya1.0 exhibited a three orders of magnitude lower affinity (KD 4.94 
- 5.45 µM). This was due to its slow association rate of 2.68 - 2.73*10E+2, as the the dissociation rate is 
only three to five times faster than for sHya2.8 and sHya1.0. The affinity constants of unmodified Hya 
and CS were not determined but assumed to be in a range comparable to HS, because the response for 
the interaction of 50 µg/ml GAGs with rhBMP-4 was comparable to HS (Figure 4). These results 
comply with those of Ruppert et al., who demonstrated the physical interaction between BMP-2 and 
immobilized heparin with a dissociation constant KD of approximately 20 nM and a rapid association 
phase (kon, of 5.1 +/- 0.8*10E+5 M-1 s-1)29.  
Obviously, besides the overall sulfate content the distribution of sulfate groups and therefore the 
number of high affinity binding sequences plays an important role in determining the affinity. Powell et 
al could show that chemically over-sulfated heparin was a marginally less effective competitor than 
heparin for binding to the FGF receptors FGFR1-Fc and FGFR2-Fc, indicating that the interactions are 
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mediated by specific sequences within the heparin chains rather than by non-specific electrostatic 
interactions33.  
In the presented study an A + B = AB Langmuir model provided the best fit for the interaction of 
GAGs and rhBMP-4. The selection of the model was based on the generated χ2 value (standard 
statistical measure of the closeness of the fit) being approximately in the same order of magnitude as the 
noise in the RU, and on the assumption that the GAG chains did not bridge multiple, adjacent proteins 
simultaneously if the lowest viable rhBMP-4 concentration was used. This was supported by biosensor 
interaction studies of immobilized heparin and dissolved BMP-2 that could also be confidently fitted on 
the basis of an A + B = AB model29. Other reports suggested that some interactions between proteins 
and heparin or HS chains could not be characterized by a single-site binding model and hence were not 
kinetically homogeneous35, 36. Obviously, the ability to characterize the interaction using single-site 
binding models is protein dependent37.  
Although a number of other SPR-analyses used the same design of dissolved GAGs and immobilized 
proteins32, 34 to determine overall dissociation constants KD, also showing high-sulfated GAGs to be 
better binders than low-sulfated ones, there are still some aspects to consider. Powell et al. for instance 
claimed that using GAGs as the dissolved binding partner could be problematic because of their low 
refractive indices, resulting in a small signal on mass basis37. Furthermore, the authors claim than the 
refractive index of GAGs could vary with the degree of sulfation, complicating a quantitative analysis 
for different chains. Consequently, Powell et al. suggest immobilizing GAGs on the sensor surface 37. 
The commonly used technique here is biotin labelling of GAGs in combination with a streptavidin-
modified sensor chip surface. However, this is also not without problems as the method of 
immobilization could affect the protein-GAG interactions. Osmond et al. demonstrated that heparin 
immobilization via the reducing terminus resulted in a higher binding capacity and in some cases a 
higher affinity for heparin-binding proteins compared to immobilization through intrachain uronic acids 
or amines38. Therefore directing biotinylation to the reducing end as developed for heparin and heparin-
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derived oligosaccharides is likely to be the least intrusive and most closely resembles a proteoglycan 
form of GAGs38-41.  
In the ELISA studies performed using immobilized GAGs to support the findings of the SPR-analysis 
these were consequently attached to the polystyrene surface via their reducing ends42.  
In general the ELISA results corroborated the ranking of binding to rhBMP-4 as determined in SPR 
analysis (Figure 4 and Table 2). The tightest binding could be demonstrated for sHya2.8, followed by 
sHya1.0, while unmodified Hya, CS and HS exhibited significantly weaker interactions (Figure 5 and 
6). The results provide support for the assumption that the nature of binding is not severely affected by 
which partner is immobilized and which is dissolved. To ensure that the observed effects where not due 
to different GAG concentrations immobilized on the plate, a competition ELISA in which dissolved 
GAGs compete for binding to rhBMP-4 with immobilized sHya2.8 was performed, which largely 
confirmed the SPR and ELISA results.  
It revealed that dissolved sHya2.8 was the most potent competitor for the interaction of dissolved 
rhBMP-4 with immobilized sHya2.8 (IC50 1.3*10E-9 g/ml ± 6.8*10E-9 g/ml), while sHya.1.0 (IC50 
4.5*10E-3 g/ml ± 2.1*10E-7 g/ml) exhibited competition abilities which are two orders of magnitude 
weaker (Figure 7). The results obtained prove the specificity of the interactions of rhBMP-4 with GAGs. 
The differences of the IC50-values are also close to the differences in affinity (KD) between these Hya 
derivatives determined by SPR (Table 2). Since results from both ELISA strategies are consistent, we 
assume comparable immobilization levels of all GAGs on direct ELISA plates. 
Interestingly in all three experimental approaches the unmodified, non-sulfated Hya seems to exhibit a 
binding strength comparable to CS and HS. This may be due in part to the fact that for the same 
mass/volume ratios the total number of disaccharide units is slightly higher for unmodified Hya than for 
CS and HS, as due to the missing sulfate groups the molecular weight of its disaccharide units is slightly 
lower. Because the interaction with rhBMP-4 is mainly electrostatic, additional non-sulfated but 
negatively charged disaccharide units might cause an increased binding response. We furthermore 
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speculate that an unsulfated GAG such as Hya may have a different binding profile due to possible 
additional binding forces like van der Waals and hydrogen bonding43. 
The obtained differences in binding affinities of the sulfated GAGs could be explained by the partial 
sulfation of the C-4 position in addition to a complete sulfation of the C-6 position in the N-
acetylglucosamine unit of sHya2.8, as Miyazaki et al. found that the C-4, C-6-disulfated structure of the 
N-acetylglucosamine unit is important for strong binding to BMP-430. The strongest interaction was 
displayed by sHya2.8, which is fully sulfated in the C-6 and partially in the C-4 position. SHya1.0 and 
CS with their significantly lower binding, on the other hand, are primarily monosulfated. The fact that 
CS bound still less than sHya1.0 despite a comparable degree of total sulfation may be due to the fact 
that sHya1.0 is sulfated mainly in the C-6 position and marginally in C-4, while CS carries most sulfate 
groups in the C-4 position. This hypothesis has to be confirmed with a greater range of structures, 
especially a sHya specifically sulfated in C-4 rather than C-6 position, to convincingly distinguish 
positional from density effects. 
 
Conclusion 
We have demonstrated specific interactions between sHya derivatives and rhBMP-4 with different 
binding affinities depending on sulfation degree, with an additional influence of the sulfate position. The 
differentially sulfated Hyas are therefore promising model substances for reaching a further 
understanding of the structure-function relationships of GAGs. Furthermore, they might be interesting 
candidates for bioengineered coatings to improve the biological properties of biomaterials by possibly 
attracting growth factors from the blood stream.  
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